Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

GeneDx Holdings (WGS) Acquisitions (2023 - 2025)

GeneDx Holdings has reported Acquisitions over the past 2 years, most recently at -$339000.0 for Q4 2025.

Quarterly Acquisitions changed N/A to -$339000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$339000.0 through Dec 2025, up 97.21% year-over-year, with the annual reading at $32.9 million for FY2025, N/A changed from the prior year.
Acquisitions was -$339000.0 for Q4 2025 at GeneDx Holdings, up from -$12.1 million in the prior quarter.
Over five years, Acquisitions peaked at -$339000.0 in Q4 2025 and troughed at -$12.1 million in Q4 2023.